• Something wrong with this record ?

Quantification of systemic delivery of substrates for intermediate metabolism during citrate anticoagulation of continuous renal replacement therapy

M. Balik, M. Zakharchenko, M. Otahal, J. Hruby, F. Polak, K. Rusinova, Z. Stach, J. Vavrova, A. Jabor,

. 2012 ; 33 (1-3) : 80-7.

Language English Country Switzerland

Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc12034811

Grant support
NS10014 MZ0 CEP Register

BACKGROUND: There are limited data on systemic delivery of metabolic substrates during citrate anticoagulation. The direct citrate measurements are usually not available. METHODS: Patients on 2.2% acid-citrate-dextrose (ACD, n = 41) were compared to a control group on unfractionated heparin (n = 17). All were treated on 1.9-m(2) polysulfone filters. Samples were taken from the central venous catheter, ports pre- and post-filter and from effluent. RESULTS: The gain of citrate in CVVH (n = 18) was not different from CVVHDF (n = 23, p = 0.8). Mean gain of citrate was 25.4 ± 6.4 mmol/h. The systemic loads of lactate (p = 0.12) and glucose (p = 0.23) in CVVH were similar to CVVHDF. Mean inputs of lactate and glucose were 62.9 ± 21.1 and 26.6 ± 10.4 mmol/h, respectively. The mean difference between post- and prefilter unmeasured anions (d-UA) correlated with mean difference of citrate concentrations (p < 0.0001, r(2) = 0.66). The estimated caloric load of the citrate modalities was 5,536 ± 1,385 kJ/ 24 h. CONCLUSIONS: ACD might represent a significant load of metabolic substrates, particularly if used with lactate buffer. Systemic delivery of citrate can be predicted using d-UA in the extracorporeal circuit.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12034811
003      
CZ-PrNML
005      
20230803073627.0
007      
ta
008      
121023s2012 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1159/000334641 $2 doi
035    __
$a (PubMed)22212643
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Balík, Martin $7 xx0075661 $u Department of Anesthesiology and Intensive Care, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. martin.balik@post.cz
245    10
$a Quantification of systemic delivery of substrates for intermediate metabolism during citrate anticoagulation of continuous renal replacement therapy / $c M. Balik, M. Zakharchenko, M. Otahal, J. Hruby, F. Polak, K. Rusinova, Z. Stach, J. Vavrova, A. Jabor,
520    9_
$a BACKGROUND: There are limited data on systemic delivery of metabolic substrates during citrate anticoagulation. The direct citrate measurements are usually not available. METHODS: Patients on 2.2% acid-citrate-dextrose (ACD, n = 41) were compared to a control group on unfractionated heparin (n = 17). All were treated on 1.9-m(2) polysulfone filters. Samples were taken from the central venous catheter, ports pre- and post-filter and from effluent. RESULTS: The gain of citrate in CVVH (n = 18) was not different from CVVHDF (n = 23, p = 0.8). Mean gain of citrate was 25.4 ± 6.4 mmol/h. The systemic loads of lactate (p = 0.12) and glucose (p = 0.23) in CVVH were similar to CVVHDF. Mean inputs of lactate and glucose were 62.9 ± 21.1 and 26.6 ± 10.4 mmol/h, respectively. The mean difference between post- and prefilter unmeasured anions (d-UA) correlated with mean difference of citrate concentrations (p < 0.0001, r(2) = 0.66). The estimated caloric load of the citrate modalities was 5,536 ± 1,385 kJ/ 24 h. CONCLUSIONS: ACD might represent a significant load of metabolic substrates, particularly if used with lactate buffer. Systemic delivery of citrate can be predicted using d-UA in the extracorporeal circuit.
650    _2
$a akutní poškození ledvin $x terapie $7 D058186
650    _2
$a antikoagulancia $x metabolismus $x terapeutické užití $7 D000925
650    _2
$a kyselina citronová $x metabolismus $x terapeutické užití $7 D019343
650    _2
$a design vybavení $7 D004867
650    _2
$a glukosa $x analogy a deriváty $x metabolismus $x terapeutické užití $7 D005947
650    _2
$a heparin $x terapeutické užití $7 D006493
650    _2
$a lidé $7 D006801
650    _2
$a kyselina mléčná $x metabolismus $7 D019344
650    _2
$a prospektivní studie $7 D011446
650    _2
$a náhrada funkce ledvin $x přístrojové vybavení $x metody $7 D017582
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Zakharchenko, Mikhailo $7 xx0304761
700    1_
$a Otáhal, Michal, $d 1973- $7 xx0093885
700    1#
$a Hrubý, Jan. $7 _AN070674
700    1_
$a Polák, Ferdinand, $d 1972- $7 xx0079883
700    1#
$a Rusinová, Kateřina. $7 jo2014809730
700    1_
$a Stach, Zdeněk $7 xx0141314
700    1_
$a Vávrová, Jaroslava, $d 1958- $7 xx0014618
700    1_
$a Jabor, Antonín, $d 1953- $7 mzk2003165648
773    0_
$w MED00000812 $t Blood purification $x 1421-9735 $g Roč. 33, č. 1-3 (2012), s. 80-7
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22212643 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20121023 $b ABA008
991    __
$a 20230803073622 $b ABA008
999    __
$a ok $b bmc $g 956821 $s 792308
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 33 $c 1-3 $d 80-7 $i 1421-9735 $m Blood purification $n Blood Purif $x MED00000812
GRA    __
$a NS10014 $p MZ0
LZP    __
$a Pubmed-20121023

Find record

Citation metrics

Archiving options